Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Increased risk of severe vaso-occlusive episodes after initial acute chest syndrome in children with sickle cell anemia less than 4 years old: Sleep and asthma cohort
source: American Journal of Hematology
year: 2015
authors: Vance LD, Rodeghier M, Cohen RT, Rosen CL, Kirkham FJ, Strunk RC, DeBaun MR
summary/abstract:Previous studies have shown that the highest incidence of acute chest syndrome (ACS) in sickle cell disease occurs in children <4 years old, and a history of ACS at this age is a risk factor for future ACS episodes. However, the interval associated with the highest risk of subsequent ACS or severe pain is not known. Through this mixed retrospective-prospective observational study, the Sleep and Asthma Cohort, we sought to determine the interval after an initial ACS episode during which the majority of children <4 years old are rehospitalized for ACS or severe pain. The cumulative prevalence of rehospitalization for ACS or severe pain within 6 months, 1 years, and 2 years was calculated for children with an initial ACS episode <4 years old and compared to children with an initial ACS episode ≥4 years old. A total of 44.8% and 55.2% of participants had an initial ACS episode <4 years and ≥4 years old (Range: 4-17.7 years), respectively. At 1 year following the initial ACS episode, children <4 years old had a significantly higher cumulative prevalence of rehospitalizations for ACS or pain as compared to children ≥4 years of age, 62.5 and 39.1%, respectively (P = 0.009). After initial ACS episodes, the majority of children <4 years old will be rehospitalized for ACS or severe pain within one year, suggesting the need for a therapeutic intervention for this high-risk group.
organization: Vanderbilt University School of Medicine, Vanderbilt University Medical Center, NashvilleDOI: 10.1002/ajh.23959
read more full text
+myBinderRelated Content
-
Desire for Parenthood and Reproductive Health Knowledge in Adolescents and Young Adults With Sickle Cell Disease and...Background/Objective: Sickle cell disea...
-
Webinar Series: Sickle Cell Science: Path to Progress – Bone Marrow Transplants, Other Therapies, and Sickle C...To commemorate Sickle Cell Awareness Mon...
-
Kwaku Ohene-Frempong, MD (Remembering)We are devastated to learn of the death ...
-
Transfusion Medicine, An Issue of Hematology/Oncology Clinics of North AmericaBlood transfusions are an important part...
-
Duke University Comprehensive Sickle Cell CenterHematologists at the Duke University Com...
-
Orphan Drug Designation Granted for CSL Behring’s Investigational Plasma-Derived Hemopexin Therapy for Sickle ...Global biotherapeutics leader CSL Behrin...
-
WNY Girl Gets First Pediatric Bone Marrow Transplant for Sickle Cell in BuffaloKayla Rushing is the first pediatric pat...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
SomeBodyToTalkTo connects people affected by rare diseases with trusted resources, supportive communities, and opportunities to share their experiences.